Repeated and Aggressive Pulmonary Resections for Leiomyosarcoma Metastases Extends Survival

被引:62
作者
Burt, Bryan M. [1 ]
Ocejo, Santiago [1 ]
Mery, Carlos M. [1 ]
Dasilva, Marcelo [1 ]
Bueno, Raphael [1 ]
Sugarbaker, David J. [1 ]
Jaklitsch, Michael T. [1 ]
机构
[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Thorac Surg, Boston, MA 02115 USA
关键词
SOFT-TISSUE SARCOMA; LONG-TERM SURVIVAL; CANCER-CENTERS; CHEMOTHERAPY; EXTREMITY; PATTERNS; GRADE; MANAGEMENT; DISEASE; BENEFIT;
D O I
10.1016/j.athoracsur.2011.05.052
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Sarcoma frequently metastasizes to the lungs, and pulmonary metastasectomy is the only treatment modality that can provide a cure for these patients. We attempted to determine the clinicopathologic features and survival determinants of a common subset of patients who undergo pulmonary metastasectomy for leiomyosarcoma. Methods. All patients undergoing pulmonary metastasectomy at The Brigham and Women's Hospital from 1989 to 2004 were reviewed retrospectively. Analyzed variables included number, size, pathology, and location of metastases, age, gender, location of primary tumor, disease-free interval (DFI), surgical approach, margin status, adjuvant therapy, recurrence, number of metastasectomies, and disease-free and overall survival. Results. Eighty-two patients underwent pulmonary metastasectomy for metastases from sarcoma. Leiomyosarcoma was the most common histologic finding (n = 31; 38%). Fifteen patients with leiomyosarcoma (48%) underwent repeated pulmonary metastasectomy. Patients with leiomyosarcoma were more commonly female (77% versus 43%; p = 0.031), less frequently received chemotherapy for their primary tumor (48% versus 71%, p = 0.041), and presented with fewer number of pulmonary metastases than did patients with nonleiomyosarcoma metastases (1.9 +/- 1.5 standard deviation [SD] versus 3.6 +/- 4.4; p = 0.033). Although there was no difference in disease-free survival, patients with leiomyosarcoma demonstrated improved overall survival compared with those with nonleiomyosarcoma metastases (70 versus 24 months; p = 0.049). In multivariate analyses, the DFI from primary tumor resection to pulmonary metastases and the DFI from pulmonary metastasectomy to second pulmonary recurrence were identified as independent predictors of survival. Conclusions. Leiomyosarcoma is a common subset of sarcomatous pulmonary metastases that behave more indolently compared with other pulmonary metastases from sarcoma. Long-term survival is achievable with an aggressive approach toward pulmonary metastasectomy and repeated pulmonary metastasectomy. (Ann Thorac Surg 2011;92:1202-7) (C) 2011 by The Society of Thoracic Surgeons
引用
收藏
页码:1202 / 1207
页数:6
相关论文
共 40 条
  • [31] LUNG METASTASECTOMY IN PATIENTS WITH SOFT-TISSUE SARCOMA
    ROBINSON, MH
    SHEPPARD, M
    MOSKOVIC, E
    FISHER, C
    [J]. BRITISH JOURNAL OF RADIOLOGY, 1994, 67 (794) : 129 - 135
  • [32] Factors associated with actual long-term survival following soft tissue sarcoma pulmonary metastasectomy
    Smith, R.
    Pak, Y.
    Kraybill, W.
    Kane, J. M., III
    [J]. EJSO, 2009, 35 (04): : 356 - 361
  • [33] UEDA T, 1993, CANCER, V72, P1919, DOI 10.1002/1097-0142(19930915)72:6<1919::AID-CNCR2820720621>3.0.CO
  • [34] 2-D
  • [35] van Geel A N, 1994, Eur J Surg Oncol, V20, P436
  • [36] Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens - A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
    Van Glabbeke, M
    van Oosterom, AT
    Oosterhuis, JW
    Mouridsen, H
    Crowther, D
    Somers, R
    Verweij, J
    Santoro, A
    Buesa, J
    Tursz, T
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 150 - 157
  • [37] VERAZIN GT, 1992, ARCH SURG-CHICAGO, V127, P1407
  • [38] VEZERIDIS MP, 1983, ARCH SURG-CHICAGO, V118, P915
  • [40] Localized extremity soft tissue sarcoma: Improved knowledge with unchanged survival over time
    Weitz, J
    Antonescu, CR
    Brennan, MF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) : 2719 - 2725